A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers

Cancer Prevention Research

Volumn 3, Issue 12, 2010, Pages 1565-1570

  Kolesar, Jill M ^a,b   Hoel, Ryan ^b   Pomplun, Marcia ^b   Havighurst, Tom ^a,b   Stublaski, Jeanne ^b   Wollmer, Barbara ^b   Krontiras, Helen ^d   Brouillette, Wayne ^d   Muccio, Donald ^d   Kim, Kyungmann ^a,b   Grubbs, Clinton J ^d   Bailey, Howard E ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9CUAB30; RETINOIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ANION GAP; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRUG METABOLISM; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NAUSEA AND VOMITING; NORMAL HUMAN; PRIORITY JOURNAL; RASH; SIDE EFFECT; URINALYSIS;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PILOT PROJECTS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 78650311702     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0149     Document Type: Article

References (17)

1. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 2006;13:51-68
2. Crowe DL, Chandraratna RAS. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-a is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 2004;6:R546-55.
3. Grubbs CJ, Hill DL, Bland KI, Beenken SW, Lin TH, Eto I, et al. 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett 2003;201:17-24
4. Love KW, DeAngelis TJ, Berletch JB, Phipps SM, Andrews LG, Brouillette WJ, et al. The novel retinoid, 9cUAB30, inhibits telomerase and induces apoptosis in HL60 cells. Transl Oncol 2008;1(3):148-52
5. Hansen NJ, Wylie RC, Phipps SMO, Love WK, Andrews LG, Tollefsbol TO. The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells. Int J Oncol 2007;30:641-50.
6. Tanaka T, De Luca LM. Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res 2009;69(12):4945-7.
7. Zusi CF, Lorenzi MV, Vivat-Hannah V. Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov Today 2002;7:1165-74.
8. Brtko J, Thalhamer J. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr Pharm Design 2003;9:2067-77.
9. Atigadda VR, Vines KK, Grubbs CJ, Hill DL, Beenken SL, Bland KI, et al. Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(30,40-Dihydro- 10(20H)-naphthalen-10-ylidene)- 3,7-dimethyl-2,4,6-octatrienoic Acid (9cUAB30). J Med Chem 2003;46:3766-9
10. Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 2006;27:1232-9.
11. Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, et al. Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biol Ther 2009;8:289-298.
12. Jackson PJ, Kabirov KK, Izet KM, Lyubimov A. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes. Chem-Biol Interact 2009;179:263-272.
13. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0, revised August 9. National Cancer Institute ; 2006. Available from: http://ctep.cancer.gov.
14. Kane MA, Folias AE, Wang C, Napoli JL. Quantitative profiling of endogenous retinoic acid in vivo and in vitro by tandem mass spectrometry. Anal Chem 2008;80:1702-8. (Pubitemid 351429576)
15. Muccio DD, Brouillette WJ, Breitman TR, Taimi M, Emanuel PD, Zhang X, et al. Conformationally defined retinoic acid analogues 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J Med Chem 1998;41:1679-87.
16. Hansen NJ, Wylie RC, Phipps SM, Love WK, Andrews LG, Tollefsbol TO. The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells. Int J Oncol 2007;30(3):641-50
17. Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, et al. Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biol Ther 2009;8(3):289-98.